These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 21129603)

  • 21. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.
    Colucci G; Giuliani F; Garufi C; Mattioli R; Manzione L; Russo A; Lopez M; Parrella P; Tommasi S; Copetti M; Daniele B; Pisconti S; Tuveri G; Silvestris N; Maiello E
    Oncology; 2010; 79(5-6):415-22. PubMed ID: 21474966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The genomic landscape of response to EGFR blockade in colorectal cancer.
    Bertotti A; Papp E; Jones S; Adleff V; Anagnostou V; Lupo B; Sausen M; Phallen J; Hruban CA; Tokheim C; Niknafs N; Nesselbush M; Lytle K; Sassi F; Cottino F; Migliardi G; Zanella ER; Ribero D; Russolillo N; Mellano A; Muratore A; Paraluppi G; Salizzoni M; Marsoni S; Kragh M; Lantto J; Cassingena A; Li QK; Karchin R; Scharpf R; Sartore-Bianchi A; Siena S; Diaz LA; Trusolino L; Velculescu VE
    Nature; 2015 Oct; 526(7572):263-7. PubMed ID: 26416732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.
    Italiano A; Hostein I; Soubeyran I; Fabas T; Benchimol D; Evrard S; Gugenheim J; Becouarn Y; Brunet R; Fonck M; François E; Saint-Paul MC; Pedeutour F
    Ann Surg Oncol; 2010 May; 17(5):1429-34. PubMed ID: 20049644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.
    Montagut C; Iglesias M; Arumi M; Bellosillo B; Gallen M; Martinez-Fernandez A; Martinez-Aviles L; Cañadas I; Dalmases A; Moragon E; Lema L; Serrano S; Rovira A; Rojo F; Bellmunt J; Albanell J
    Br J Cancer; 2010 Mar; 102(7):1137-44. PubMed ID: 20234366
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
    Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
    Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer.
    Pander J; Gelderblom H; Antonini NF; Tol J; van Krieken JH; van der Straaten T; Punt CJ; Guchelaar HJ
    Eur J Cancer; 2010 Jul; 46(10):1829-34. PubMed ID: 20418097
    [TBL] [Abstract][Full Text] [Related]  

  • 27. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.
    De Roock W; De Vriendt V; Normanno N; Ciardiello F; Tejpar S
    Lancet Oncol; 2011 Jun; 12(6):594-603. PubMed ID: 21163703
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Targeted therapies for metastatic colorectal cancer].
    Kito Y; Yamazaki K
    Nihon Rinsho; 2015 Aug; 73(8):1384-90. PubMed ID: 26281694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. KRAS mutation testing in human cancers: The pathologist's role in the era of personalized medicine.
    Wang HL; Lopategui J; Amin MB; Patterson SD
    Adv Anat Pathol; 2010 Jan; 17(1):23-32. PubMed ID: 20032635
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer.
    Sartore-Bianchi A; Bencardino K; Di Nicolantonio F; Pozzi F; Funaioli C; Gambi V; Arena S; Martini M; Lamba S; Cassingena A; Schiavo R; Bardelli A; Siena S
    Target Oncol; 2010 Mar; 5(1):19-28. PubMed ID: 20383783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?
    Bronte G; Silvestris N; Castiglia M; Galvano A; Passiglia F; Sortino G; Cicero G; Rolfo C; Peeters M; Bazan V; Fanale D; Giordano A; Russo A
    Oncotarget; 2015 Sep; 6(28):24780-96. PubMed ID: 26318427
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient-tailored treatments with anti-EGFR monoclonal antibodies in advanced colorectal cancer: KRAS and beyond.
    Ballestrero A; Garuti A; Cirmena G; Rocco I; Palermo C; Nencioni A; Scabini S; Zoppoli G; Parodi S; Patrone F
    Curr Cancer Drug Targets; 2012 May; 12(4):316-28. PubMed ID: 22385512
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BEYOND KRAS: Other markers and potential treatment strategies for KRAS mutant and wild-type patients.
    Cercek A; Saltz L
    Curr Treat Options Oncol; 2011 Jun; 12(2):126-35. PubMed ID: 21472513
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current approaches for predicting a lack of response to anti-EGFR therapy in KRAS wild-type patients.
    Er TK; Chen CC; Bujanda L; Herreros-Villanueva M
    Biomed Res Int; 2014; 2014():591867. PubMed ID: 25032217
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRAF testing in advanced colorectal cancer: is it ready for prime time?
    Phillips B; Kalady M; Kim R
    Clin Adv Hematol Oncol; 2010 Jun; 8(6):437-44. PubMed ID: 20733556
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients.
    Perrone F; Lampis A; Orsenigo M; Di Bartolomeo M; Gevorgyan A; Losa M; Frattini M; Riva C; Andreola S; Bajetta E; Bertario L; Leo E; Pierotti MA; Pilotti S
    Ann Oncol; 2009 Jan; 20(1):84-90. PubMed ID: 18669866
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting EGFR in metastatic colorectal cancer beyond the limitations of KRAS status: alternative biomarkers and therapeutic strategies.
    Caiazza F; Elliott L; Fennelly D; Sheahan K; Doherty GA; Ryan EJ
    Biomark Med; 2015; 9(4):363-75. PubMed ID: 25808440
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Xu JM; Wang Y; Wang YL; Wang Y; Liu T; Ni M; Li MS; Lin L; Ge FJ; Gong C; Gu JY; Jia R; Wang HF; Chen YL; Liu RR; Zhao CH; Tan ZL; Jin Y; Zhu YP; Ogino S; Qian ZR
    Clin Cancer Res; 2017 Aug; 23(16):4602-4616. PubMed ID: 28424201
    [No Abstract]   [Full Text] [Related]  

  • 39. Targeting mechanisms of resistance to anti-EGF receptor therapy in KRAS wild-type colorectal cancer: the path to more personalized medicine.
    Fakih M
    Future Oncol; 2013 Apr; 9(4):551-60. PubMed ID: 23560377
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer.
    Di Fiore F; Sesboüé R; Michel P; Sabourin JC; Frebourg T
    Br J Cancer; 2010 Dec; 103(12):1765-72. PubMed ID: 21139621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.